Video

Dr. Wong on treatment sequence in metastatic urothelial carcinoma

Author(s):

Urology Times staff

Risa Wong, MD, discusses the sequencing of treatments in the metastatic urothelial carcinoma armamentarium, including chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates. Wong is a hematology/oncology fellow at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert is featured in this series.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Related Content
Anktiva targets expanded indication in US and global approvals in EU and UK
January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke
The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial
January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke
“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor
Results from CREST will be presented at an upcoming medical conference.
FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC
January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke
"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.
© 2025 MJH Life Sciences

All rights reserved.